Intrexon

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Investors need to pay close attention to Intrexon (XON) stock based on the movements in the options market lately.

Do Options Traders Know Something About Intrexon (XON) Stock We Don't?

Intrexon (XON) inks a $100-million worth exclusive licensing deal with Surterra to produce cannabinoid in a reliable and cost-effective fashion, using its own yeast fermentation process. Shares climb.

Intrexon Up on Striking 100M Cannabinoid Deal With Surterra

A big deal with a medical cannabis company provided a spark for Intrexon.

Why Intrexon Stock Popped Today

Intrexon Corporation (NASDAQ: XON) announced a $100 million partnership with Surterra Wellness to advance its cannabinoid production.

Intrexon Strikes $100M Partnership With Surterra For Cannabinoid Production

Chemours

Guess?

Odonate Therapeutics

Details the CEO buys this past week for the following companies: Guess?, Intrexon, Odonate Therapeutics, The Chemours and i3 Verticals

Weekly CEO Buys Highlight June 17

CEO of Intrexon Corp (NASDAQ:XON) Randal J Kirk bought 483,268 shares of XON on 06/07/2019 at an average price of $5.24 a share.

Intrexon Corp (XON) CEO Randal J Kirk Bought $2.5 million of Shares

American Airlines

Capri Holdings Ltd

Freeport-McMoRan

According to GuruFocus Insider Data, these are the largest CEO buys during the past week.

Weekly CEO Buys Highlight June 10

Intrexon (XON) reported earnings 30 days ago. What's next for the stock?

Intrexon (XON) Up 24.7% Since Last Earnings Report: Can It Continue?

Intrexon Corp (XON) CEO Randal J Kirk Bought $998,306 of Shares

AGNC Investment

Discovery

Eidos Therapeutics Inc

Weekly CEO Buys Highlight June 3

Zillow

Medicines

Conventional wisdom says that insiders and 10 percent owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it.

Notable Insider Buys This Past Week: Coty, Zillow and More

Biotechnology company Intrexon Corp (NASDAQ: XON) CEO Randal Kirk made five bundles of large purchases of the company's stock over the month of May.

Intrexon CEO Made Big Open-Market Bets In May

CEO of Intrexon Corp (NASDAQ:XON) Randal J Kirk bought 495,271 shares of XON on 05/30/2019 at an average price of $4.75 a share.

Intrexon Corp (XON) CEO Randal J Kirk Bought $2.4 million of Shares

ARMOUR Residential REIT

Bunge Global SA

Cognizant Technology Solutions

Details the CEO buys this past week

Intrexon (XON) reports in line loss in the first quarter of 2019. Also, sales miss estimates.

Intrexon (XON) Reports In-Line Q1 Loss, Misses on Revenues

Intrexon (XON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Intrexon (XON) to Report a Decline in Earnings: What to Look Out for

Investors weren't happy to learn about its worsening cash position.

Why Intrexon Stock Dropped 34% in March

Why Is Intrexon (XON) Down 34% Since Last Earnings Report?

News for Intrexon Stock (XON)